Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,484,462
  • Shares Outstanding, K 384,396
  • Annual Sales, $ 6,848 M
  • Annual Income, $ -4,714 M
  • EBIT $ -4,635 M
  • EBITDA $ -4,075 M
  • 60-Month Beta 1.69
  • Price/Sales 3.01
  • Price/Cash Flow N/A
  • Price/Book 1.76

Options Overview Details

View History
  • Implied Volatility 81.10% ( +0.65%)
  • Historical Volatility 30.16%
  • IV Percentile 97%
  • IV Rank 83.34%
  • IV High 88.94% on 11/01/24
  • IV Low 41.88% on 05/17/24
  • Put/Call Vol Ratio 0.80
  • Today's Volume 88,046
  • Volume Avg (30-Day) 50,692
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 555,389
  • Open Int (30-Day) 534,100

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.89
  • Number of Estimates 12
  • High Estimate -0.98
  • Low Estimate -2.58
  • Prior Year -1.39
  • Growth Rate Est. (year over year) -35.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.60 +4.46%
on 11/06/24
60.65 -14.58%
on 10/07/24
-8.39 (-13.94%)
since 10/04/24
3-Month
49.60 +4.46%
on 11/06/24
91.99 -43.68%
on 08/19/24
-30.49 (-37.05%)
since 08/06/24
52-Week
49.60 +4.46%
on 11/06/24
170.47 -69.61%
on 05/24/24
-20.26 (-28.11%)
since 11/06/23

Most Recent Stories

More News
These Are the 5 Worst-Performing Stocks in the S&P 500 With 2024 Almost Over

Perhaps this list is a good place to start bargain-hunting.

INTC : 25.05 (+7.42%)
DLTR : 62.41 (-6.53%)
WBA : 9.23 (-4.05%)
EL : 63.28 (-3.92%)
MRNA : 51.81 (-2.78%)
Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today.

SMCI : 22.70 (-18.05%)
IDXX : 423.42 (+1.79%)
REGN : 816.65 (-1.54%)
MRNA : 51.81 (-2.78%)
DELL : 138.35 (+3.66%)
ASML : 661.43 (-2.22%)
What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week.The remaining large...

NVO : 105.36 (-4.33%)
VTRS : 11.61 (unch)
TEVA : 17.43 (-7.14%)
GILD : 91.69 (+1.63%)
MRNA : 51.81 (-2.78%)
Moderna Stock Slips On Report Of CEO Relinquishing Sales Chief Role: Retail Mood Dims

Moderna's COVID-19 vaccine windfall is now a thing of the past as it struggles to shore up revenue and reverse to a profit.

IBB : 146.60 (+1.06%)
MRNA : 51.81 (-2.78%)
SPY : 591.04 (+2.49%)
XBI : 102.44 (+1.81%)
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share,...

MRK : 100.73 (-0.91%)
MRNA : 51.81 (-2.78%)
GSK : 35.90 (-3.03%)
PFE : 27.36 (-2.25%)
Option Volatility And Earnings Report For November 4 - 8

We have some important companies with Palantir, Super Micro computer, Block, Moderna, Qualcomm, Arista Networks, Gilead Sciences and Airbnb all set to report.

QCOM : 172.99 (+4.27%)
GILD : 91.69 (+1.63%)
FSLY : 8.16 (+6.39%)
MRNA : 51.81 (-2.78%)
AMZN : 207.09 (+3.80%)
PLTR : 55.53 (+8.61%)
BMY : 55.28 (-1.20%)
ANET : 423.12 (+4.44%)
AAPL : 222.72 (-0.33%)
SMCI : 22.70 (-18.05%)
MSTR : 257.81 (+13.17%)
ABNB : 140.91 (+2.24%)
2 Dividend Stocks to Buy for a Lifetime of Passive Income

These are the kinds of stocks that can allow investors to sleep easy at night.

MRK : 100.73 (-0.91%)
SMMT : 20.89 (+2.45%)
MDT : 90.11 (+0.48%)
MRNA : 51.81 (-2.78%)
ISRG : 515.55 (+0.07%)
Stocks Close Higher on Reduced Middle East Risks

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.68%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.12%. Stocks rallied...

UAL : 87.58 (+9.43%)
AAPL : 222.72 (-0.33%)
CVX : 157.72 (+2.81%)
MRO : 28.80 (+4.35%)
ABNB : 140.91 (+2.24%)
$IUXX : 20,781.33 (+2.74%)
COIN : 254.31 (+31.11%)
ZNZ24 : 109-210 (+0.10%)
OXY : 51.39 (+1.96%)
FANG : 183.62 (+4.55%)
SBUX : 96.08 (-1.04%)
$DOWI : 43,729.93 (+3.57%)
Stocks Higher on Relief After Israel's Limited Retaliation Reduces Middle East Risks

The S&P 500 Index ($SPX ) (SPY ) is up +0.40%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. Stocks today are trading higher on reduced...

UAL : 87.58 (+9.43%)
AAPL : 222.72 (-0.33%)
CVX : 157.72 (+2.81%)
MRO : 28.80 (+4.35%)
ABNB : 140.91 (+2.24%)
$IUXX : 20,781.33 (+2.74%)
COIN : 254.31 (+31.11%)
ZNZ24 : 109-210 (+0.10%)
OXY : 51.39 (+1.96%)
TSLA : 288.53 (+14.75%)
FANG : 183.62 (+4.55%)
SBUX : 96.08 (-1.04%)
Earnings Preview: What to Expect From Moderna's Report

Moderna is all set to release its fiscal third-quarter earnings next month, and analysts project its loss to rise in double digits.

XLV : 148.04 (+0.13%)
$SPX : 5,929.04 (+2.53%)
MRNA : 51.81 (-2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 56.50
2nd Resistance Point 54.68
1st Resistance Point 53.24
Last Price 51.81
1st Support Level 49.99
2nd Support Level 48.17
3rd Support Level 46.73

See More

52-Week High 170.47
Fibonacci 61.8% 124.30
Fibonacci 50% 110.04
Fibonacci 38.2% 95.77
Last Price 51.81
52-Week Low 49.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar